Global cosentyx drug market is estimated to be valued at USD 5.32 Bn in 2024, and is expected to reach USD 8.74 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.
Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds and inhibits interleukin-17A (IL-17A), a proinflammatory cytokine that is involved in neutrophil recruitment and activation. Launched in 2015 by Novartis, Cosentyx is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in over 80 countries worldwide. Within the first few years of its launch, it has established itself as one of the top selling drugs, capturing a sizable market share due to its high efficacy and favorable safety profile.
Market Dynamics:
Global cosentyx drug market growth is driven by rising prevalence of immune-mediated inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. Growing awareness about the availability of targeted biologic drugs and their superior efficacy over conventional therapies are driving the market growth. The continuous pipeline expansion through new indications and strengths is expanding the eligible patient pool. However, the drug's patent expiration in major regions by 2027, combined with the market entry of different IL-17 targeting biosimilars, may impede the growth of Cosentyx to some extent. The geographical expansion into emerging markets and development of novel drug delivery systems with improved formulations offer lucrative opportunities for sustained revenues over the long-run.
Key Features of the Study:
Detailed Segmentation:
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients